GlassScriptPhysician profile
Claudia Najar
NPI 1659821841
$6,439.93
in general payments reported to CMS, 2019-2025
26 companies · $2,063 in 2025
The $2,063 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $649 · 2023: $1,039 · 2024: $2,174 · 2025: $2,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,031 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.03 |
| Education | $244.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $834.19 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Incyte Corporation | $681.62 | 2023-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $654.48 | 2022-2025 | |
| Abbvie INC. | $599.62 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $543.32 | 2023-2025 | Zoryve |
| Amgen INC. | $496.11 | 2023-2025 | Otezla, Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $431.11 | 2021-2025 | Winlevi, Ilumya, Blu-U |
| Janssen Biotech, INC. | $368.40 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $366.15 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $304.34 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $178.20 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $169.80 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.29 | 2021-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $123.44 | 2023-2025 | Adbry |
| Ucb, INC. | $106.81 | 2025 | Bimzelx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Epi Health, LLC | $86.14 | 2022 | |
| Allergan, INC. | $47.20 | 2021-2022 | |
| Organon LLC | $41.38 | 2025 | Vtama |
| Pfizer INC. | $36.21 | 2024-2025 | |
| Almirall LLC | $33.03 | 2024-2025 | Seysara |
| Genzyme Corporation | $20.19 | 2024 | |
| Botanix Sb INC | $16.91 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $16.47 | 2025 | Valchlor |
| Verrica Pharmaceuticals INC. | $14.37 | 2024 | Ycanth |
| Biofrontera INC. | $14.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Najar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.